Skip to main content
Fig. 3 | Alzheimer's Research & Therapy

Fig. 3

From: Cerebrospinal fluid phospho-tau T217 outperforms T181 as a biomarker for the differential diagnosis of Alzheimer’s disease and PET amyloid-positive patient identification

Fig. 3

Site occupancy of phosphorylation on T181 and T217 in the two cohorts. The percentage of T181 and T217 phosphorylation corresponding to the amount of the phosphorylated peptide divided by the sum of the phosphorylated and non-phosphorylated peptide was plotted in the two cohorts. Significant differences between NAD and AD or amyloid (−) and (+) populations for the two peptides were observed (see also Sup Table 2)

Back to article page

Alzheimer's Research & Therapy

ISSN: 1758-9193